Table 1.
Direct evidence of rescue treatment in PDE5i nonresponders.
| Approaches for rescue treatment in PDE5i nonresponders | PDE5i nonresponse | Rescue therapy with/without PDE5is | Ref. | ||||||
|---|---|---|---|---|---|---|---|---|---|
| PDE5i | Dosage | Dosing regimen | PDE5i | Dosage | Dosing regimen | Other therapeutic approaches | Salvage success rate | ||
| Increased PDE5i doses | Sildenafil | 100 mg | On demand | Sildenafil | 150 or 200 mg | On demand | NA | 24.1% | 38 |
| Different dosing regimens | Tadalafil | 20 mg | On demand | Tadalafil | Flexible doses of 10 and 20 mg | Once daily | NA | 58.0% | 46 |
| Different dosing regimens | Vardenafil | 20 mg | On demand | Vardenafil | 10 mg | Once daily | NA | 38.8% | 47 |
| Different PDE5is | Sildenafil | 100 mg | On demand | Vardenafil | Flexible doses of 10 and 20 mg | On demand | NA | 12.0% | 48 |
| Different PDE5is | Sildenafil | ≤100 mg | On demand | Vardenafil | Flexible doses of 5, 10 and 20 mg | On demand | NA | 53.0% | 49 |
| Non-drug therapeutic approaches with or without PDE5is | At least one PDE5i (20 mg for tadalafil or vardenafil hydrochloride, 100 mg for sildenafil) | Taking the same PDE5i as PDE5i nonresponse | VED | 70.0% | 59 | ||||
| Non-drug therapeutic approaches with or without PDE5is | Tadalafil | 5?mg | Once daily | NA | NA | NA | LiSWT | 41.7% | 62 |
| Non-drug therapeutic approaches with or without PDE5is | PDE5is (unclear in detail) | NA | NA | NA | LiSWT | 60.0% | 63 | ||
| Non-drug therapeutic approaches with or without PDE5is | Sildenafil (100 mg), tadalafil (20 mg), and vardenafil (20 mg) as needed or tadalafil (5 mg) daily | Taking the same PDE5i as PDE5i nonresponse | LiSWT | 67.3% | 64 | ||||
| Attention to psychological factors | Sildenafil | 100 mg | On demand | Sildenafil | 100 mg | On demand | Trazodone (50 or 100 mg, once daily) | 66.7% | 68 |
| PDE5is combined with other non-PDE5i drugs | Highest available dosage of sildenafil, tadalafil, or vardenafil therapy | Tadalafil | 10 mg | Once daily | Testogel (5 g up to 10 g, once daily) | 33.1% | 110 | ||
| PDE5is combined with other non-PDE5i drugs | Sildenafil | 100 mg | On demand | Sildenafil | 100 mg | On demand | Oral testosterone undecanoate (Restandol, 80 mg, bid or tid) | 34.3% after testosterone replacement only, 37.5% more after combined therapy | 111 |
| PDE5is combined with other non-PDE5i drugs | Tadalafil | 20 mg | On demand | Tadalafil | 20 mg | Twice a week | Testogel (5 g, once daily) | NA (improvement in IIEF-EF) | 113 |
| PDE5is combined with other non-PDE5i drugs | Sildenafil | 100 mg | On demand | Sildenafil | 100 mg | On demand | Atorvastatin (40 mg, once daily) | NA (significant improvements in all IIEF-5 questions and GEQ) | 117 |
Salvage success is defined as being able to successfully complete sexual intercourse. NA, not applicable; VED, vacuum erectile device; LiSWT, low-intensity shockwave therapy; IIEF, international index of erectile function; EF, erectile function; GEQ, global efficacy question.